Acrivon Therapeutics Inc. (ACRV): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
ACRV Stock Price Chart Interactive Chart >
ACRV Price/Volume Stats
| Current price | $11.61 | 52-week high | $25.47 |
| Prev. close | $20.00 | 52-week low | $10.90 |
| Day low | $11.25 | Volume | 203,500 |
| Day high | $20.07 | Avg. volume | 76,025 |
| 50-day MA | $17.78 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 242.47M |
Latest ACRV News From Around the Web
Below are the latest news stories about ACRIVON THERAPEUTICS INC that investors may wish to consider to help them evaluate ACRV as an investment opportunity.
Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare ConferenceWATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company’s chief executive officer and president, Peter Blume-Jensen, M.D., Ph |
Acrivon Therapeutics to Participate on a Panel at Cowen’s 43rd Annual Health Care ConferenceCEO to participate on ovarian cancer panel and will highlight ACR-368, a DNA Damage Response (DDR) inhibitor in clinical testing for platinum-resistant advanced ovarian cancer and other solid tumorsWATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specifi |
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) insider upped their holding earlier this yearLooking at Acrivon Therapeutics, Inc.'s ( NASDAQ:ACRV ) insider transactions over the last year, we can see that... |
2 Breakout Growth Stocks to Buy for the Long HaulAs a result, it's never a bad idea to consider buying equities with strong forward momentum. Here are two healthcare stocks that have been breaking out this year in response to clear-cut catalysts, making them worth considering as long-term buy and holds. Acrivon Therapeutics (NASDAQ: ACRV) is a relative newcomer to the publicly traded biopharma scene, with the drugmaker's shares debuting on the Nasdaq stock exchange last November. |
13 Cheap New Stocks To BuyIn this article, we will take a look at the 13 cheap new stocks to buy. To see more such companies, go directly to 5 Cheap New Stocks To Buy. Global markets were rattled by the market crash of 2022 whose reverberations are expected to affect equities for several months to come. However, prudent investors […] |
ACRV Price Returns
| 1-mo | -46.23% |
| 3-mo | -2.60% |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 0.78% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...